07/12/2018 17:53:26

ImmusanT Chief Scientific Officer Robert Anderson, Ph.D. to Participate as a Featured Speaker During the Antigen-Specific Immune Tolerance Europe Conference 2018

CAMBRIDGE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, announced today that Robert (Bob) Anderson, Ph.D., will be among the featured speakers during the Antigen-Specific Immune Tolerance Europe Conference 2018 in London from Dec. 10-12, 2018.

“I am delighted to have been invited to participate as a featured speaker during this conference,” said Dr. Anderson. “We have made significant strides in the discovery and development of immune tolerizing therapeutics that have the potential to transform how we treat patients with autoimmune disorders. I look forward to sharing my insights with other experts in the field.” 

The conference is the first, European centric platform that brings together key decision makers to discuss the translation of groundbreaking science into novel therapies that address significant unmet needs in a variety of autoimmune disorders.

About ImmusanT, Inc.

At ImmusanT, we are developing a new class of therapeutic vaccines to change the lives of people living with autoimmune diseases. Our Epitope-Specific Immuno-Therapy™ (ESIT™) platform provides a precision medicine approach to restoring immune tolerance across a range of diseases, including celiac disease and type 1 diabetes. Our lead program, Nexvax2®, is in clinical development with the goal of protecting celiac disease patients against the debilitating effects of gluten. www.ImmusanT.com 

Media Contact:

Andrew Mielach

Account Supervisor

LifeSci Public Relations

(646) 876-5868

amielach@lifescipublicrelations.com  

 

immusanT_logo_031111.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
17 Feb
VWS
  Jeg har nu haft lidt tid til at læse det seneste årsregnskab fra Vestas. Jeg har forsøgt at opsumm..
62
21 Feb
VELO
Især 2 ting har fanget min opmærksomhed i de seneste døgn. 1) Astellas er udtrådt af AST )American S..
22
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
21 Feb
CHEMM
Vi sidder her under træet og bliver helt skizofrene. Hvad skete der lige her. Tælleren tog et hop op..
18
19 Feb
FING-B
Så lukkede FPC over den gamle modstand i dag i 19,55 modstanden var 19,47 og næste stop er nu 21,786..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
18
18 Feb
VWS
VESTAS LEADS BREAK-AWAY GROUP OF ONSHORE TURBINE MAKERS (fra 16% til 22% af det totale marked for la..
17
18 Feb
PNDORA
Det er netop kommet frem, at tyske BAFIN, svarende til Finanstilsynet i Dk., har forbudt short posit..
17
19 Feb
VELO
Til dem af jer der ikke er med i FB gruppen: Canada havde, sammen med US, lukket i går. Teorien er, ..
16
18 Feb
CHEMM
Puha, ja hvad venter vi nu på,…… vi trofaste og frelste Chemo aktionærer, Noten, den romantiske og ..
15

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen
2
Bragar Eagel & Squire, P.C. is Investigating Domino’s Pizza, Inc. (DPZ) on Behalf of Stockholders and Encourages DPZ Investors to Contact the Firm
3
Melinta Therapeutics Announces One-for-Five Reverse Stock Split
4
Odyssey Moon Extends Its Heartfelt Congratulations to SpaceIL for the Successful Launch of the First Non-Governmental Spacecraft to the Moon
5
Bragar Eagel & Squire, P.C. is Investigating Vanda Pharmaceuticals Inc. (VNDA) on Behalf of Stockholders and Encourages VNDA Investors to Contact the Firm

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 February 2019 09:12:37
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB4 - 2019-02-22 10:12:37 - 2019-02-22 09:12:37 - 1000 - Website: OKAY